Twist Bioscience Corporation (NASDAQ: TWST) reported Q1 EPS of ($0.75), $0.03 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $71.5 million versus the consensus estimate of $67.49 million.

GUIDANCE:

Twist Bioscience Corporation sees Q2 2024 revenue of $288-293 million, versus the consensus of $289.7 million.

SynBio revenue is expected to be in the range of $114 million to $117 million compared to the previous estimate of $113 million to $116 million, indicating year over year growth of 16 to 19 percent
NGS revenue is expected to be in the range of $150 million to $152 million compared to the previous estimate of $147 million to $149 million, indicating year over year growth of 21 to 23 percent
Biopharma revenue is expected to be approximately $24 million compared to the previous estimate of approximately $25 million, indicating year over year growth of approximately 3 percent

Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range
Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously
Capital expenditure of $15 million, a decrease of $5 million from prior guidance
Ending cash, cash equivalents and short-term investments at September 30, 2024 of approximately $245 million, unchanged from previous guidance

For the second quarter of fiscal year 2024, Twist provided the following financial guidance:

Total revenue of approximately $70 million to $71 million, versus the consensus of $67.601 million.

SynBio revenue of approximately $28.5 million
NGS revenue of approximately $37 million to $38 million
Biopharma revenue of approximately $4.5 million

Gross margin of 39%

For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.